MCID: CRY005
MIFTS: 58

Cryptococcosis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Cryptococcosis

MalaCards integrated aliases for Cryptococcosis:

Name: Cryptococcosis 12 74 52 58 54 15 17 32
Infection by Cryptococcus Neoformans 71
Cryptococcus Neoformans Infection 12
Busse-Buschke's Disease 12
European Cryptococcosis 12
Cryptococcal Infection 12
Torulosis 12
Torula 12

Characteristics:

Orphanet epidemiological data:

58
cryptococcosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Cryptococcosis

Disease Ontology : 12 An opportunistic mycosis that results in fungal infection and has material basis in Cryptococcus neoformans or Cryptococcus gattii.

MalaCards based summary : Cryptococcosis, also known as infection by cryptococcus neoformans, is related to cryptococcal meningitis and acquired immunodeficiency syndrome. An important gene associated with Cryptococcosis is SELL (Selectin L), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Fluconazole and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are fever and immunodeficiency

Wikipedia : 74 Cryptococcosis, sometimes informally called crypto, is a potentially fatal fungal disease caused by a... more...

Related Diseases for Cryptococcosis

Diseases related to Cryptococcosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 671)
# Related Disease Score Top Affiliating Genes
1 cryptococcal meningitis 32.7 PLB1 MBL2 IFNG CD8A CD4 CCR6
2 acquired immunodeficiency syndrome 31.5 IFNG FCGR3A CD4 CCR6
3 meningitis 31.3 MBL2 IL4 IFNG FCGR2A
4 lymphopenia 31.1 SELL IL4 IFNG CCR6
5 pulmonary tuberculosis 31.1 MBL2 IL4 IFNG
6 lupus erythematosus 31.1 IFNG FCGR3B FCGR3A FCGR2A
7 meningoencephalitis 31.0 PLB1 IL4 CD8A CD4 CCR6
8 aspergillosis 31.0 MBL2 IL4 IFNG CLEC7A CCR6
9 sarcoidosis 1 30.9 IFNG CD8A CD4 CCR6
10 cellulitis 30.9 IL4 IFNG CD8A CD4 CCR6
11 lymphadenitis 30.9 IFNG CD4 CCR6
12 chorioretinitis 30.9 IFNG CD8A CD4
13 histoplasmosis 30.8 IFNG CLEC7A CD8A CD4 CCR6
14 mucormycosis 30.8 IFNG CLEC7A CD4 CCR6
15 candidiasis 30.8 PLB1 MBL2 IL4 IFNG CLEC7A CCR6
16 miliary tuberculosis 30.7 IFNG CD8A CD4
17 pneumocystosis 30.7 CLEC7A CD8A CD4 CCR6
18 bacterial pneumonia 30.7 CD8A CD4 CCR6
19 tularemia 30.7 MBL2 CD8A CD4 CCR6
20 penicilliosis 30.7 IFNG CLEC7A CD4
21 immune deficiency disease 30.7 SELL MBL2 IL4 IFNG FCGR3B FCGR3A
22 blastomycosis 30.7 CLEC7A CLEC6A CD4 CCR6
23 lymph node tuberculosis 30.7 IFNG CD4
24 immunodeficiency with hyper-igm, type 1 30.7 IL4 CD4 CCR6
25 allergic hypersensitivity disease 30.6 SELL IL4 IFNG CD4 CCR6
26 neutropenia 30.6 MBL2 IFNG FCGR3B FCGR3A
27 pneumonia 30.5 SELL MBL2 IL4 IFNG CD8A
28 crohn's disease 30.5 IL4 IFNG CD4 CCR6
29 coccidioidomycosis 30.5 MBL2 CLEC7A CLEC6A CD4 CCR6
30 sporotrichosis 30.4 MBL2 IFNG CLEC7A CD4
31 oral candidiasis 30.4 CLEC7A CLEC6A CD8A CD4 CCR6
32 esophageal candidiasis 30.4 CD8A CD4 CCR6
33 ocular tuberculosis 30.4 IFNG CD4
34 salmonellosis 30.4 IFNG CD8A CD4 CCR6
35 epidermodysplasia verruciformis 1 30.3 CD8A CD4 CCR6
36 exanthem 30.2 IFNG CD8A CD4 CCR6
37 pleural disease 30.2 IFNG CD8A CD4 CCR6
38 thrombocytopenia 30.2 SELL MBL2 IL4 IFNG FCGR3A FCGR2A
39 chickenpox 30.2 IL4 IFNG CD8A CD4 CCR6
40 invasive aspergillosis 30.2 MBL2 IFNG CLEC7A CLEC6A CD4 CCR6
41 allergic bronchopulmonary aspergillosis 30.1 MBL2 IL4 IFNG
42 cerebritis 30.1 CD8A CD4
43 progressive multifocal leukoencephalopathy 30.1 CD8A CD4 CCR6
44 pulmonary disease, chronic obstructive 30.1 IL4 CD8A CD4 CCR6
45 t cell deficiency 30.0 SELL CD8A CD4 CCR6
46 central nervous system vasculitis 30.0 IFNG CD8A CD4 CCR6
47 dermatophytosis 30.0 CLEC7A CLEC6A CD4 CCR6
48 temporal arteritis 30.0 IFNG CD8A CD4 CCR6
49 cholangitis, primary sclerosing 30.0 CD8A CD4 CCR6
50 fungal infectious disease 30.0 PLB1 IL4 IFNG CLEC7A CLEC6A CD8A

Comorbidity relations with Cryptococcosis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcal Meningitis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcosis:



Diseases related to Cryptococcosis

Symptoms & Phenotypes for Cryptococcosis

Human phenotypes related to Cryptococcosis:

58 31 (show all 43)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
2 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
3 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
4 nodular pattern on pulmonary hrct 58 31 frequent (33%) Frequent (79-30%) HP:0025392
5 behavioral abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0000708
6 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
7 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
8 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
9 cirrhosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001394
10 chest pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0100749
11 cerebral cortical atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002120
12 mental deterioration 58 31 occasional (7.5%) Occasional (29-5%) HP:0001268
13 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
14 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
15 mediastinal lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0100721
16 respiratory distress 58 31 occasional (7.5%) Occasional (29-5%) HP:0002098
17 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
18 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
19 systemic lupus erythematosus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002725
20 limb muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003690
21 nuchal rigidity 58 31 occasional (7.5%) Occasional (29-5%) HP:0031179
22 blindness 58 31 very rare (1%) Very rare (<4-1%) HP:0000618
23 memory impairment 58 31 very rare (1%) Very rare (<4-1%) HP:0002354
24 osteomyelitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002754
25 osteolysis 58 31 very rare (1%) Very rare (<4-1%) HP:0002797
26 ophthalmoplegia 58 31 very rare (1%) Very rare (<4-1%) HP:0000602
27 abnormal cranial nerve morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0001291
28 sepsis 58 31 very rare (1%) Very rare (<4-1%) HP:0100806
29 prostatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0000024
30 peritonitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002586
31 abnormality of the optic nerve 58 31 very rare (1%) Very rare (<4-1%) HP:0000587
32 abnormality of the outer ear 58 31 very rare (1%) Very rare (<4-1%) HP:0000356
33 abnormal retinal morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0000479
34 cerebral edema 58 31 very rare (1%) Very rare (<4-1%) HP:0002181
35 vitritis 58 31 very rare (1%) Very rare (<4-1%) HP:0011531
36 lymphoid leukemia 58 31 very rare (1%) Very rare (<4-1%) HP:0005526
37 seizure 31 very rare (1%) HP:0001250
38 seizures 58 Very rare (<4-1%)
39 dyspnea 58 Occasional (29-5%)
40 autoimmunity 58 Occasional (29-5%)
41 neoplasm 58 Occasional (29-5%)
42 abnormality of the eye 58 Occasional (29-5%)
43 abnormality of vision 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Cryptococcosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR6 CD4 CD8A CLEC6A CLEC7A FCGR2A
2 immune system MP:0005387 9.36 CCR6 CD4 CD8A CLEC6A CLEC7A FCGR2A

Drugs & Therapeutics for Cryptococcosis

Drugs for Cryptococcosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
2
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
5
Voriconazole Approved Phase 4 137234-62-9 71616
6
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
7
Zidovudine Approved Phase 4 30516-87-1 35370
8
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10 Hormone Antagonists Phase 4
11 Cytochrome P-450 Enzyme Inhibitors Phase 4
12 Hormones Phase 4
13 Liposomal amphotericin B Phase 4
14 Antimetabolites Phase 4
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16 Reverse Transcriptase Inhibitors Phase 4
17 Anti-HIV Agents Phase 4
18 Anti-Retroviral Agents Phase 4
19 Antiviral Agents Phase 4
20 Trace Elements Phase 4
21 Micronutrients Phase 4
22 Vitamins Phase 4
23 Nutrients Phase 4
24 Calciferol Phase 4
25 Calcium, Dietary Phase 4
26
Calcium Nutraceutical Phase 4 7440-70-2 271
27
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
28
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
29
Isavuconazole Approved, Investigational Phase 3 241479-67-4
30
Sertraline Approved Phase 3 79617-96-2 68617
31 Amebicides Phase 3
32 Antiparasitic Agents Phase 3
33 Antiprotozoal Agents Phase 3
34 Anti-Bacterial Agents Phase 3
35 Pharmaceutical Solutions Phase 3
36
Hydroxyitraconazole Phase 3
37 Anti-Infective Agents, Local Phase 3
38 Antidepressive Agents Phase 3
39 Psychotropic Drugs Phase 3
40 Serotonin Uptake Inhibitors Phase 3
41 Neurotransmitter Agents Phase 3
42
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
44
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
45
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
46
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
47
Flucytosine Approved, Investigational Phase 2 2022-85-7 3366
48 Gastrointestinal Agents Phase 2
49 Antineoplastic Agents, Hormonal Phase 2
50 Antiemetics Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
2 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
3 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
4 Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
5 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
6 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
7 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
8 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
9 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034658 Phase 3 Posaconazole
10 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034632 Phase 3 Posaconazole oral suspension
11 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
12 A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis Recruiting NCT03471988 Phase 3 AK1820;Voriconazole
13 Cryptococcal Antigen Screening Plus Sertraline Terminated NCT03002012 Phase 3 Sertraline;Placebo Oral Tablet;Fluconazole
14 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
15 Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts Completed NCT00034671 Phase 2 Posaconazole oral suspension
16 An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone Terminated NCT01562132 Phase 2 Flucytosine and fluconazole;Fluconazole
17 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
18 A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection Withdrawn NCT03196921 Phase 1, Phase 2 Encochleated Amphotericin B
19 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
20 Multi-center Clinical Trial of Pulmonary Cryptococcosis in China Unknown status NCT02503449
21 Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1 Unknown status NCT03267407
22 Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection Completed NCT00001701
23 Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia Completed NCT02113930
24 Special Investigation Of Fluconazole For Pediatric Subjects Completed NCT01680458 Fluconazole
25 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Fluconazole
26 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002305 Flucytosine;Fluconazole;Amphotericin B
27 Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002294 Fluconazole
28 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Flucytosine;Fluconazole;Amphotericin B
29 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Fluconazole;Amphotericin B
30 Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection Completed NCT00002438 Itraconazole
31 Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B Completed NCT00002306 Fluconazole
32 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002077 Fluconazole
33 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Fluconazole;Amphotericin B
34 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002040 Fluconazole
35 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Amphotericin B, Lipid-based;Amphotericin B
36 AIDS Defining Opportunistic Infections in Naive HIV Cases Completed NCT03993093
37 Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. Completed NCT00830856 Fluconazole;Fixed dose - Stavudine, lamivudine and Nevirapine;Fixed dose - Stavudine, Lamivudine, Nevirapine
38 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Itraconazole;Flucytosine;Fluconazole;Amphotericin B
39 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Flucytosine;Fluconazole
40 Plasma Nevirapine Levels and Adverse Events Among HIV-Infected Patients Concurrently Receiving Nevirapine-Based Antiretroviral Therapy and Fluconazole Completed NCT00309582
41 A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients With CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy Completed NCT00286767
42 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Flucytosine;Fluconazole;Amphotericin B
43 AIDS-Associated Heart Disease -- Incidence and Etiology Completed NCT00005228
44 Cryptococcosis in Previously Healthy Adults Recruiting NCT00001352
45 Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models Recruiting NCT02015013
46 Vicente Ferrer HIV Cohort Study Recruiting NCT02454569
47 Making an Early Diagnosis of Talaromycosis - a Strategy to Reduce Morbidity and Mortality in Advanced HIV Disease in Southeast Asia Not yet recruiting NCT04033120

Search NIH Clinical Center for Cryptococcosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Itraconazole

Genetic Tests for Cryptococcosis

Anatomical Context for Cryptococcosis

MalaCards organs/tissues related to Cryptococcosis:

40
Lung, Testes, Liver, Skin, Brain, T Cells, Bone

Publications for Cryptococcosis

Articles related to Cryptococcosis:

(show top 50) (show all 5081)
# Title Authors PMID Year
1
Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection. 54 61
15776384 2005
2
First case of feline cryptococcosis in Hong Kong, caused by Cryptococcus neoformans. 61
32477859 2020
3
Mass-forming hepatic cryptococcosis: a mimicker of metastatic tumors. 61
32036416 2020
4
Wall-eyed bilateral internuclear ophthalmoplegia: A rare presentation of central nervous system cryptococcosis. 61
32361333 2020
5
Cryptococcal pericarditis in a heart transplant recipient. 61
32533755 2020
6
Pulmonary cryptococcosis coexisting with central type lung cancer in an immuocompetent patient: a case report and literature review. 61
32503511 2020
7
17-β-Estradiol increases macrophage activity through activation of the G-protein-coupled estrogen receptor and improves the response of female mice to Cryptococcus gattii. 61
32017324 2020
8
Microbiological and clinical characteristics of cryptococcemia: a retrospective analysis of 85 cases in a Chinese hospital. 61
31504739 2020
9
Dormancy in Cryptococcus neoformans: 60 years of accumulating evidence. 61
32484459 2020
10
Fungal prostatitis due to endemic mycoses and Cryptococcus: A multicenter case series. 61
32572997 2020
11
Anticryptococcal activity of hexane extract from Spondias tuberosa Arruda and associated cellular events. 61
32307255 2020
12
Incorporation of 2-amino-thiophene derivative in nanoparticles: enhancement of antifungal activity. 61
32141030 2020
13
Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent. 61
31297540 2020
14
FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages. 61
32484801 2020
15
Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod. 61
32126512 2020
16
Burden of serious fungal infections in the Netherlands. 61
32297377 2020
17
Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center. 61
32510755 2020
18
IL-25 Receptor Signaling Modulates Host Defense against Cryptococcus neoformans Infection. 61
32561567 2020
19
Cryptococcal antigenemia and its predictors among HIV infected patients in resource limited settings: a systematic review. 61
32527231 2020
20
The Novel J-Domain Protein Mrj1 Is Required for Mitochondrial Respiration and Virulence in Cryptococcus neoformans. 61
32518190 2020
21
Cryptococcal osteomyelitis of the Zygomatic bone: a case report. 61
32503446 2020
22
The Added Value of Longitudinal Imaging for Preclinical In Vivo Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis. 61
32284382 2020
23
Cryptococcus neoformans infection in Human Immunodeficiency Virus (HIV)-infected and HIV-uninfected patients at an inner-city tertiary care hospital in the Bronx. 61
31342058 2020
24
Cryptococcus neoformans/Cryptococcus gattii species complex melanized by epinephrine: Increased yeast survival after amphotericin B exposure. 61
32169493 2020
25
Solitary Pulmonary Nodule as a Form of Presentation of Cryptococcosis in a Renal Transplant Recipient. 61
31926752 2020
26
Cryptococcosis in an HIV-negative, HCV positive, immunosenescent patient: a case report. 61
32510160 2020
27
New Perspectives from Misdiagnosis: A Case of Primary Cutaneous Cryptococcosis Treated with Hydroxychloroquine Sulfate Successfully. 61
32419069 2020
28
Clinical analysis in immunocompetent and immunocompromised patients with pulmonary cryptococcosis in western China. 61
32523003 2020
29
Skin cryptococcosis in an immunocompromised renal-transplant recipient. 61
32346501 2020
30
Clinicopathological features of isolated pulmonary cryptococcosis in HIV-negative patients. 61
32527202 2020
31
Disseminated Cryptococcosis After Liver Transplant: A Case Report. 61
30696395 2020
32
New ST623 of Cryptococcus neoformans isolated from a patient with non-Hodgkin's lymphoma in the Brazilian Amazon. 61
32434527 2020
33
Fenbendazole Controls In Vitro Growth, Virulence Potential, and Animal Infection in the Cryptococcus Model. 61
32253211 2020
34
Regulation of key molecules of immunological synapse by T11TS immunotherapy abrogates Cryptococcus neoformans infection in rats. 61
32388483 2020
35
Drug Repurposing of Haloperidol: Discovery of New Benzocyclane Derivatives as Potent Antifungal Agents against Cryptococcosis and Candidiasis. 61
31550886 2020
36
Indoor Dust as a Source of Virulent Strains of the Agents of Cryptococcosis in the Rio Negro Micro-Region of the Brazilian Amazon. 61
32392852 2020
37
Persistent eyelid ulceration in an immunocompromised host: A cutaneous sign with the potential for early diagnosis and intervention in disseminated cryptococcosis. 61
32382625 2020
38
Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: Clinical features and associated factors. 61
31758642 2020
39
Localized Tracheal Cryptococcosis Misdiagnosed as Severe Refractory Asthma. 61
32459503 2020
40
Pulmonary Cryptococcosis Accidentally Detected by 68Ga-Pentixafor PET/CT in a Patient With Multiple Myeloma. 61
32209881 2020
41
Cryptococcal pneumonia in a human immunodeficiency virus-negative patient: A case report. 61
32518798 2020
42
Core N-Glycan Structures Are Critical for the Pathogenicity of Cryptococcus neoformans by Modulating Host Cell Death. 61
32398313 2020
43
Involvement of Mrs3/4 in mitochondrial iron transport and metabolism in Cryptococcus neoformans. 61
32522963 2020
44
Cutaneous and pulmonary cryptococcosis. 61
32299737 2020
45
Steroid resistance in organizing pneumonia caused by pulmonary cryptococcosis. 61
32280465 2020
46
Landmark clinical observations and immunopathogenesis pathways linked to HIV and Cryptococcus fatal central nervous system co-infection. 61
32472727 2020
47
Unusual case of primary cutaneous cryptococcosis. 61
32369659 2020
48
Clinical and Radiological Features of Patients With Pulmonary Cryptococcosis in a Hospital of North China. 61
32537279 2020
49
Transmission of cryptococcosis by liver transplantation: A case report and review of literature. 61
32547692 2020
50
Disseminated cutaneous cryptococcosis in an immunocompetent elderly long-term pigeon fancier. 61
32096254 2020

Variations for Cryptococcosis

Expression for Cryptococcosis

Search GEO for disease gene expression data for Cryptococcosis.

Pathways for Cryptococcosis

GO Terms for Cryptococcosis

Cellular components related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 SELL FCGR3B FCGR3A FCGR2A CD8A CD4
2 extracellular region GO:0005576 9.61 MBL2 IL4 IFNG FCGR3B FCGR3A CGB8
3 secretory granule membrane GO:0030667 9.43 SELL FCGR3B FCGR2A
4 external side of plasma membrane GO:0009897 9.02 SELL FCGR3A CD8A CD4 CCR6

Biological processes related to Cryptococcosis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.97 MBL2 FCGR2A CLEC7A CLEC6A CD8A CD4
2 cell surface receptor signaling pathway GO:0007166 9.73 IFNG FCGR3B FCGR3A FCGR2A CD8A CD4
3 immune response GO:0006955 9.7 IL4 IFNG FCGR3B FCGR3A CD8A CD4
4 hormone-mediated signaling pathway GO:0009755 9.63 CGB8 CGB7 CGB3
5 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.54 CLEC7A CD4
6 positive regulation of phagocytosis GO:0050766 9.54 MBL2 IFNG CLEC7A
7 positive regulation of chemokine biosynthetic process GO:0045080 9.52 IL4 IFNG
8 positive regulation of MHC class II biosynthetic process GO:0045348 9.51 IL4 IFNG
9 female gamete generation GO:0007292 9.5 CGB8 CGB7 CGB3
10 positive regulation of killing of cells of other organism GO:0051712 9.48 IFNG CLEC7A
11 positive regulation of cellular respiration GO:1901857 9.43 IL4 IFNG
12 neuroinflammatory response GO:0150076 9.4 IL4 IFNG
13 T cell activation GO:0042110 9.26 IL4 CLEC7A CD8A CD4
14 regulation of immune response GO:0050776 9.1 SELL IL4 FCGR3B FCGR3A FCGR2A CD8A

Molecular functions related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.26 SELL MBL2 CLEC7A CLEC6A
2 IgG binding GO:0019864 8.8 FCGR3B FCGR3A FCGR2A

Sources for Cryptococcosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....